Where Our Funds Go
We have listed in the table below a list of the grants we have awarded to date. We have colour coded the grants to show how we are supporting the whole therapeutic development pipeline.
Joining Jack is committed to ensuring that as much as possible of our funds goes to developing research into a treatment or a cure for Duchenne Muscular Dystrophy. We are particularly focused on transitional research, research that takes potential therapeutics out of laboratories and into clinical trials.
Working closely with our partner charity Duchenne UK, our trusted team of scientific advisors, patient advisory board and trustees we have made major decisions on how to spend the funds that we have raised. The grants that we have awarded have led to breakthroughs that are changing the therapeutic landscape for the Duchenne community.
Filter by Project Type:
| Project Name | Research/Institution or Company | Project Status | Total Grant Award |
|---|---|---|---|
| Smart Suit Project | Spinal Muscular Atrophy UK (SMA UK) & University of Liverpool | Ongoing | £150,000 |
| DMD Care Phase 2 | Newcastle University | Ongoing | £150,000 |
| DMD Hub research Fellow/ Clinical Trial Support | Dr Anne-Marie Childs, Leeds Children’s Hospital | Ongoing | £35,000 |
| Home-based video assessment of DMD | Aparito | Ongoing | £173,336 |
| DMD Care Neuropsychiatrist | University of Glasgow | Complete | £75,000 |
| Antifibrotic/antiadipogenic drug Fibrogenesis | Newcastle University | Complete | £32,688 |
| Hydrotherapy Clinical Trial | Dr De Geode, Royal Preston Hospital | Started | £118,000 |
| Immunology Grant Call Award | Professor Kanneboyina Nagaraju at Binghamton, the State University of New York | Started | £1,000 |
| Biomarker Trial | Duke University | Started | £20,000 |
| Dream Chair development | Whizz Kidz | Ongoing | £50,000 |
| DMD Care UK | Newcastle University | Ongoing | £140,000 |
| Immunology Grant | University of Florida | Ongoing | £185,000 |
| Splint Trial | Newcastle University | Started | £10,000 |
| Stem Cells | University of Minnesota | Started | £140,000 |
| Vitamin B3 | Leiden University | Started | £10,000 |
| Tackling fibrosis and muscle regeneration | Agada Biosciences | Started | £25,000 |
| Repurposing Drugs | Dr Olivier Dorchies, University of Geneva | Started | £25,000 |
| Testosterone extension | Prf Volker Straub, University of Newcastle | Started | £10,000 |
| Adult NMCCC | Dr Chiara Marini-Bettolo, University of Newcastle | Ongoing | £10,000 |
| Open label extension study for Tamoxifen | Dr Dirk Fischer, University Children’s Hospital Basel | Pending | £230,000.00 |
| Taurine | Dr Peter Arthur, Senior Lecturer, The University of Western Australia | Ongoing | £50,000 |
| Fibrosis | Dr Lee Borthwich, University of Newcastle | Ongoing | £10,000 |
| New ways of delivering Gene Therapy | EVOX Therapeutics | Ongoing | £200,000 |
| Understanding heart disease in DMD | Dr John Bourke, Freeman Hospital | Ongoing | £67,000.00 |
| Investigating soy products as a treatment for DMD | Prof Steve Winder, University of Sheffield | Ongoing | £30,500 |
| Preclinical study of the combination of tamoxifen, L-citrulline and metformin | Dr Olivier Dorchies, University of Geneva | Ongoing | £200,000 |
| Use of Elastase Inhibitors to Treat DMD | Dr Addolorata Pisconti, University of Liverpool | Ongoing | £36,365.00 |
| Duchenne Clinical Research Nurse | Alder Hey Children’s Hospital, Liverpool | Ongoing | £32,106.50 |
| F2 Neuromuscular Clinical Research Doctor | Alder Hey Children’s Hospital, Liverpool | Complete | £30,513 |
| ST4 Neuromuscular Clinical Research Doctor | Alder Hey Children’s Hospital, Liverpool | Complete | £127,121.00 |
| Tamoxifen Clinical Trial | Dr Dirk Fischer, University Children’s Hospital Basel | Ongoing | £194,996.99 |
| Tamoxifen Project Manager | Dr Dirk Fischer, University Children’s Hospital Basel | Ongoing | £97,000 |
| TREAT-NMD DMD Co-Ordinator Role | University of Newcastle | Ongoing | £78,832.66 |
| Physiotherapist | Alder Hey Children’s Hospital, Liverpool | Complete | £45,960.00 |
| Duchenne Clinical Trial Nurse | Royal Victoria Infirmary, Newcastle | Complete | £22,500 |
| Co-Funded Lectureship for a Clinical Research Lectureship/ Senior Lectureship in Duchenne Muscular Dystrophy | Dr Guglieri, University of Newcastle | Ongoing | £35,714.30 |
| Assessing the preclinical therapeutic impact of cannabidiol for DMD | Dr Keith Foster, The University of Reading | Complete | £6213.09 |
| The Duchenne Forum, Supporting 8 basic research projects | Muscular Dystrophy Campaign | Complete | £55,346.00 |
| Gene therapy | Solid GT, Boston, USA | Complete | $1,666,666.66 |
| VBP-15, Phase 1 Clinical Trial | Reveragen BioPharma Inc, USA | Complete | $400,000.00 |
| DMD Heart Protection Study | Dr Spinty, Alder Hey | Complete | £14,000 |
| Phase1/2 Clinical trial of HT-100 | Akashi Therapeutics, USA | Complete | $100,000 |
| Developing biomarkers for Utrophin Modulators | Summit Corporation, Oxford, UK | Complete | £100,000 |